We have recently developed a micropuncture technique to assess repeatedly function of the same nephrons in chronic renal disease and subsequently examine the morphology of their glomeruli by serial thin-section histological analysis. Using this approach, a potential causal linkage between early functional patterns and late structural abnormalities was examined in glomeruli of two established rat models of glomerular sclerosis. The models are (a) puromycin aminonucleoside (PAN) administration in unilaterally nephrectomized Munich-Wistar rats and (b) adriamycin (ADM) treatment in nonnephrectomized Munich-Wistar rats. Single nephron GFR (SNGFR) and glomerular capillary hydraulic pressure (PGc) were measured repeatedly for 8 (PAN rats) or 31 wk (ADM rats). In all animals studied, values for PGC remained at, or slightly below, levels measured before PAN or ADM administration. SNGFR values declined progressively in all glomeruli in PAN rats. Although some glomeruli in ADM rats had an increase in SNGFR above levels observed in nonnephrectomized control rats, these hyperfiltering glomeruli did not have abnormally high PGC nor did they exhibit glomerular sclerosis at the completion of the study. Histological analysis revealed the existence of a significant inverse correlation between the degree of sclerosis and SNGFR assessed at the time of sacrifice in both PAN and ADM groups. Chronic administration of captopril, an angiotensin I converting enzyme inhibitor, in PAN rats substantially attenuated development of glomerular sclerosis without affecting PGC in earlier stages. The observations in these models indicate that glomerular hyperfiltration and hypertension are not required for the development of glomerular sclerosis in renal diseases, and angiotensin I converting enzyme inhibitor can exert its protective effect independently of its effect on glomerular capillary pressure.
Introduction
Puromycin aminonucleoside, or PAN,' is perhaps one of the most widely used agents in the study of experimental renal disease. Shortly after administration, animals given PAN develop glomerular lesions that are indistinguishable ultrastructurally and biochemically from human minimal change disease (1) (2) (3) (4) (5) (6) (7) (8) (9) (10) (11) (12) . Investigators (12, 13) have also noted that, when animals are treated chronically with PAN, progressive azotemia and glomerular lesions develop that remarkably resemble the mesangial expansion and glomerular sclerosis seen in a variety of human chronic renal diseases. Adriamycin (ADM) given acutely (14, 15) or chronically (16) , has been shown to have glomerular pathogenic effects virtually identical to those of PAN, although its chemical structure is different. Previous studies by us (17) and others (15) described in detail the glomerular functional pattern during the acute stage in these PAN-and ADM-treated experimental models. In those studies, reduced glomerular perfusion and filtration were noted uniformly in all nephrons in the early stage of disease. This is in marked contrast to the pattern seen in some other experimental animal models in which glomerular sclerosis also develops chronically. Thus, the model of subtotal ablation of renal mass is characterized by a marked hyperperfusion and hyperfiltration in remnant nephrons in the early stage before development of highly focal glomerular sclerotic lesions (18) . The rat model of diabetes mellitus induced by streptozotocin, although requiring many more weeks before abnormal histology becomes discernible, has also been shown to have abnormally high glomerular capillary pressure and filtration during its early stages (19) . These experimental observations have since been extrapolated and have led to theories that glomerular hyperfunction may be the common pathway present at early stages, and may play an essential role in the development of glomerular sclerosis in chronic renal diseases. Since the patterns of glomerular sclerosis that develop following PAN or ADM administration are also focal in nature (13, 16) , we suspected that those selected glomeruli in which structural abnormalities develop may represent a specific subpopulation of glomeruli, which are hypoperfused and hypofiltering initially but, unlike the other nephrons, soon become hyperfunctioning. In designing the present studies, we felt it essential, in view of the focal nature of the glomerular sclerosis in the chronic PAN and ADM models, to perform functional assessment (in early stage) and histological examination (in late stage) on the same single glomeruli. In addition, periodical monitoring of the function of these glomeruli throughout the duration of study appeared to be indicated, since the hypothesized transition from hypo-to hyperfunction in the ultimately sclerosed glomeruli might take place in an unpredictable time period. The methodology of serial micropuncture measurements developed by us recently (20) allowed us to accomplish both of these goals. As discussed in detail elsewhere (20) vigorous vali-dation tests have confirmed that the serial micropuncture procedures per se do not affect subsequent glomerular function or histology (at least at the light microscopic level) of the glomeruli subjected to functional assessment. The segmental glomerular lesions were studied by light microscopic serial section analysis, allowing semiquantitation ofthe degree of sclerosis of the whole glomerulus. By using these new techniques, we explored a causal linkage between functional pattern and structural changes within the same glomeruli in the chronic PAN and ADM rat models.
Methods

General
Experiments were performed on 49 adult Munich-Wistar rats. Experimental groups were PAN-treated rats (group I), control for PAN rats (group II), PAN-treated rats with converting enzyme inhibitor (CEI) (group III), ADM-treated rats (group IV) and control for ADM rats (group V). All animals were allowed free access to regular rat chow and tap water throughout the study except for -15 h before each micropuncture measurement when the animals were allowed water only. Blood samples were taken periodically from tail veins of awake rats to measure blood urea nitrogen (BUN). 12-h urinary collection was performed in metabolic cages periodically, and urinary protein concentration was measured. Systolic arterial pressure (SAP) was measured in anesthesized rats by the tail cuff method (21) immediately before and after micropuncture experiments, and also periodically in awake rats. During the procedures of unilateral nephrectomy, mapping of surface glomeruli or serial micropuncture procedures specified below, animals were anesthetized with sodium pentobarbital (Nembutal; Abbott Laboratories, North Chicago, IL, 25-30 mg/kg body wt, i.p.), with the exception of the final micropuncture measurements, and placed on a temperature-regulated table. All surgical instruments were sterilized with 70% ethyl alcohol. After each micropuncture procedure except during the final assessment, the abdominal incision was closed with 3-0 silk (Ethicon, Inc., Somerville, NJ), and 10,000 U of penicillin G (Wyeth Laboratories Inc., Philadelphia, PA) was injected subcutaneously. The rats were returned to their cages after recovering from anesthesia. At the final micropuncture measurements, animals were anesthetized with Inactin (Byk, FRG; 100 mg/kg body wt, i.p.). Micropuncture assessment, mean systemic arterial pressure (MAP) from left femoral artery and whole kidney GFR measurement were followed by marking ofglomeruli (specified below), and animals were sacrificed for histological studies.
Serial micropuncture measurements
Mapping of surface glomeruli and measurements of single nephron glomerular filtration rate (SNGFR), glomerular capillary hydraulic pressure (Poc), and Bowman's space hydraulic pressure (PBS) were performed in hydropenic rats as described elsewhere in detail (20) . Briefly, surface glomeruli and the earliest segment of proximal tubules originating from these glomeruli were identified by injecting a small quantity of 0.1% lissamine green into proximal convolutions in the vicinity of surface glomeruli in a retrograde manner. Geographical localization of the specific glomeruli was recorded by Polaroid photographs and sketches ofthe closest proximal tubule convolutions. These glomeruli could then be identified by these topographical maps in subsequent micropuncture studies. Precisely timed (1-2 min) fluid samples were collected from the earliest segment of proximal tubules previously identified for determination of SNGFR. PGC and Pes were measured with a continuous recording, servo-nulling pressure system (model 4A; Instrumentation for Physiology and Medicine, San Diego, CA) only in nephrons from which samples of proximal fluid were not obtained. Hydraulic output from the servo-null system was coupled electronically to a channel of the direct-writing recorder (recorder 2400S; Gould Inc., Cleveland, OH) by means of a pressure transducer.
SNGFR and PGC/PBS measurements were done on an average of 5.3 and 3.1 glomeruli per kidney, respectively. At the completion of the final micropuncture measurements, surface glomeruli on which micropuncture measurements were performed were marked by injecting a small volume of dye (The Davidson Marking System; Bradley Products, Inc., Bloomington, MN), into the subcapsular space just above, and/or into Bowman's space ofthe surface glomerulus. This dye served to identify specific glomeruli for the subsequent histological study.
The above serial micropuncture methodology and the validation of the technique are discussed in length elsewhere (20) Histological study Light microscopic examination was performed after the completion of the micropuncture studies. The kidneys were removed and immersion fixed in 10% neutral buffered formalin after marking of the glomeruli, which had been subjected to micropuncture assessment. This allowed for gross visualization of the site of the specific glomerulus studied during embedding and processing. Serial sections (3 lsm thick) were made and stained with periodic acid Schiff. A semiquantitative score (sclerosis index) was used for assessing glomerular sclerosis by the method of Raij, Azar, and Keane (22) . Each glomerulus was evaluated by a minimum of 10 sections representing an even distribution throughout the glomerulus. On each section, sclerosis was graded from 0 to 4. Grade 0 is 0% sclerosis; grade 1 is sclerosis of up to 25% of the glomerulus; grade 2 is 26-50% sclerosis; grade 3 is 51-75% sclerosis and grade 4 is 76-100% sclerosis ofthe glomerulus. The average ofthe scores from all sections of a given glomerulus was calculated to obtain the sclerosis index for the single glomerulus. A whole kidney sclerosis index was obtained by averaging scores for all glomeruli on a single thin section, with a minimum of 50 glomeruli analyzed.
Experimental groups
Group I (PAN-treated rats, n = 9). The experimental protocol for group I animals is outlined in Fig. 1 A. In 6 rats, mapping ofsurface glomeruli was followed by right unilateral nephrectomy. 2 wk later, initial micropuncture measurements were performed. On the following day, the Group IV (ADM-treated rats, n = 7). The protocol for group IV is summarized in Fig. 1 B: Seven rats were given ADM intravenously (doxorubicin hydrochloride; Sigma Chemical Co., St. Louis, MO, 0.2 mg/100 g body wt) twice with a 3-wk interval (16) . Mapping of surface glomeruli was followed by initial micropuncture measurements. Micropuncture measurements were repeated more than three times at 7, 15, 19, 23, 27 , and/or 31 wk after the first ADM administration. At the 27th or 31st week, final micropuncture measurements were followed by marking of surface glomeruli, and animals were killed for histological study.
Group V (control ratsfor ADM treatment, n = 18). 18 age-matched nonnephrectomized animals (three subgroups containing six rats each) were used as controls for ADM-treated rats. Mapping of surface glomeruli and micropuncture measurements were performed once in each of these three subgroups of six age-matched rats at 7, 15-19, or 27-31 wk.
Analytic BUN was measured using a BUN analyzer (BUN Analyzer II; Beckman Instruments, Inc., Fullerton, CA). Plasma and urine concentration of inulin for the determination ofwhole kidney GFR was assessed by the anthrone method (23) . Urine protein concentration was measured by the Coomassie Brilliant Blue method (24) . The fluid collected from the earliest segment of proximal tubules was processed for the determination of SNGFR as described in detail elsewhere (20) .
Statistical methods
Results are expressed as mean± I SE. Nonparametric data from multiple groups were tested using the Kruskall-Wallis one-way analysis of variance (ANOVA) with subsequent Mann-Whitney U test if the ANOVA indicated there were differences among groups. Parametric data from multiple groups were compared using ANOVA followed by t test with modification by Bonferroni's method. Comparisons between two groups were made by the unpaired t test. Linear regression analysis was employed to examine for correlation between sclerosis index and hemodynamic parameters. The results were deemed statistically significant when the P value was < 0.05.
Results
Animal and whole kidney data Mean values for body weight, SAP, BUN, and total urinary protein excretion (UprotV) measured immediately before PAN or saline injection and at subsequent pertinent time intervals in groups I, II, and III, are shown in Table I . Also shown are values for MAP, total GFR and whole kidney sclerosis index assessed at the time of sacrifice. Body weight measured at 0 Fig. 2 B, which presents data from a representative PAN kidney, several nephrons displayed an increase in SNGFR before a decline at the end of the study. However, no nephrons showed an increase of SNGFR above the levels measured in group II control rats. As shown by the increasing standard errors depicted by the vertical bars in Fig. 2 Data from serial SNGFR and PGc assessment in group IV ADM-treated rats is shown in Fig. 4 A-D (Fig. 4 A) . As shown in Fig. 4 41 .6 nl/min) were found by 15 wk after the first ADM injection.
Similar to PAN-treated group I, Pcc levels in ADM-treated group IV remained constant or tended to decline in almost all glomeruli (Fig. 4 D) and kidneys (Fig. 4 C) . Average baseline Histological changes at single nephron levels were compared to the time course patterns of SNGFR and Pcc, and overall changes in SNGFR and PGc. In group I PAN-treated rats, when maximum values of SNGFR in early stage (0-4 wk after the first PAN injection) were plotted against the sclerosis index for each glomerulus, no correlation was seen (r = 0.03, NS). The sclerosis index also did not correlate with baseline SNGFR (r = 0.12, NS). As shown in Fig. 5 A, however, there was a strong inverse correlation between sclerosis index and SNGFR measured at the completion of the study (r = 0.56, P The time course of Prc in group IV ADM-treated rats is given in C and D in a fashion similar to that of A and B, respectively. At 27-31 wk, there is a statistically significant difference (P < 0.01) between the average SNGFR in control and ADM-treated rats.
= 0.64, P < 0.05). Thus, some nephrons that attained higher SNGFR, showed the least degree of subsequent sclerosis. Also, as shown in Fig. 5 (18, 19) that glomerular hyperfiltration and/or hypertension is an obligatory common pathophysiologic pathway (25) , they bear no insight as to whether the glomerular hyperfunction which exists in other models indeed exerts an injurious effect on the glomerular architecture.
Since marked functional heterogenetity appears to exist in many forms of human chronic renal diseases, it is impossible to speculate on single nephron hyperfiltration from the evaluation of total kidney GFR. The animal model of subtotal renal ablation has been considered to represent an advanced stage of human chronic renal disease, primarily on the basis of their histological similarity. Glomerular hyperfiltration and hypertension have been demonstrated in the early stage of this model with subsequent glomerular sclerosis (18) . In addition, certain experimental maneuvers have been shown to modify the magnitude of these early functional changes and the degree of later structural damage (25) . Although the late stage of many experimental models histologically closely resembles the human end stage kidney, it should be noted that the initial damage in the animal model of subtotal renal ablation is extremely focal and seems to be comparable clinically to rather unusual forms of renal injury. In this regard, ADM or PAN models, where the initial insult is directed against all nephrons, appear to more closely simulate many forms of human chronic renal diseases. Our results may therefore be taken to indicate that in those human diseases where all glomeruli are initially exposed to a pathogenic insult, glomerular hyperfunction is not required for the development of glomerular sclerosis.
Having observed the serial functional changes in PAN and ADM models and demonstrated a progression of glomerular sclerosis independent of glomerular pressure and filtration, we wished to test at least one intervention that in the past has been shown to attenuate the development of glomerular sclerosis. We therefore examined if CEI exerts a protective effect on the PAN-treated rats, as found in the models of subtotal ablation of renal mass (26) and streptozotocin-induced diabetes mellitus (27). As described in Results, whereas CEI was essentially without effect on glomerular capillary pressure, it attenuated significantly and substantially the development of glomerular sclerosis in PAN rats. In a recent study of a chronic PAN model (28), ACE inhibition was not found to have a detectable protective effect on glomerular structure. Although glomerular sclerosis was quantitated by a different method, in their study only 12-13% of glomeruli had hyalinosis or sclerosis, whereas in our model the majority of glomeruli were affected. Thus, it appears that the protective effect of CEI in PAN-induced glomerular sclerosis is only demonstrable experimentally when there is more than mild glomerular sclerosis. In our study CEI did not completely ameliorate glomerular sclerosis, although it is possible that higher doses of captopril might have resulted in an even greater decrease in sclerosis. Our observations indicate that PAN-induced glomerular sclerosis was derived at least in part by CEI-sensitive mechanism(s) which operate independently of glomerular capillary pressure. Thus, in this PAN model, CEI appears to partially protect the kidney from glomerular sclerosis, and the protective effect does not appear to be channeled through a decrease in glomerular capillary pressure. Since CEI had no effect on glomerular capillary pressure in the present study, our results do not elucidate whether the association between reduction in glomerular pressure and attenuation of glomerular sclerosis following CEI seen in other experimental models is indeed a causal one (26, 27) .
How, then, did CEI attenuate the development of sclerosis in PAN-treated rats? In vivo and in vitro studies conducted in humans and animals during the past several years indicate that CEI exerts its action through both angiotensin-dependent and independent pathways (29). Moreover, a variety ofcell types in addition to smooth muscle cells, including macrophages, brain cells and T lymphocytes, have been found to have angiotensin I converting enzyme (ACE) activity (30) (31) (32) (33) (34) (35) (36) (37) . In addition, a wide variety of biological actions of CEI (and ACE) has been reported (32, (37) (38) (39) (40) . Thus, it is difficult to propose a simple scheme to explain the role of ACE and CEI on the glomerular structure in the PAN-treated rats. In a study using chronic PAN-treated rats, infusion of a competitive antagonist of angiotensin II was shown to markedly attenuate the accumulation of macromolecules in the mesangium (41) . In chronically treated PAN and subtotal nephrectomy models, the macromolecule accumulation occurs in the mesangium before sclerosis develops (42) (43) (44) . Thus, CEI may be exerting its protective effect in the current study by preventing mesangial macromolecular deposition. Alternatively, since angiotensin II is known to directly stimulate proliferation of some angiotensin 1I receptor-bearing cells (45) (46) (47) , the protective effect of CEI on the glomerular structure in PAN rats may be channeled through inhibition of a hypertrophic or mitogenic angiotensin II effect on glomerular mesangial cells (48) . Further possible mechanisms may relate to angiotensin II independent actions of CEO. CEI has been shown to enhance the cyclooxygenase pathway of arachidonic acid metabolism in blood vessels and isolated glomeruli (38, (49) (50) (51) . Products ofthe cyclooxygenase pathway, in turn, directly or indirectly attenuate cell proliferation (38, (52) (53) (54) (55) (56) (57) (58) . In our recent preliminary study a strong correlation was found between glomerular hypertrophy and sclerosis at the single nephron level in a model of subtotal nephrectomy (59). Therefore, it is conceivable that the protective effect of CEI on glomerular structure observed in the present study may be mediated by enhanced production of arachidonic acid metabolites that attenuate glomerular growth. Consistent with this concept is our observation of significant attenuation of glomerular maturational growth when CEI was given to young rats, although there was no effect on PGc (60). Moreover, prostaglandins of both exogenous and endogenous origin were shown to inhibit glomerular cell proliferation and mesangial matrix formation in vitro (61) .
In summary, the studies presented in this article show that in the PAN and ADM models sclerosis occurs without preceding glomerular hypertension or hyperfiltration. Additionally, CEI treatment diminished sclerosis substantially without affecting the glomerular capillary pressure, thus further supporting our conclusion that nonhemodynamic factors are instrumental in the production of glomerular sclerosis in these two experimental models.
